Moomoo AI 已提取核心訊息
ZyVersa Therapeutics, Inc. has announced a special meeting of stockholders to be held virtually on April 17, 2024. The primary agenda is to seek approval for a reverse stock split of issued common stock at a ratio between 1-for-2 and 1-for-50, at the board's discretion, without further stockholder approval. This move aims to avoid delisting from Nasdaq, attract brokerage firms and investors, and facilitate future financings. The company also seeks approval to adjourn the meeting if necessary to solicit more votes for the reverse stock split. The record date for determining stockholders eligible to vote is March 5, 2024. The company encourages stockholders to vote by proxy prior to the meeting, with detailed voting instructions provided. The reverse stock split is intended as a recapitalization for tax purposes, with no gain or loss recognized by the company or stockholders. The board recommends voting 'FOR' both the reverse stock split and the potential adjournment.
ZyVersa Therapeutics, Inc. has announced a special meeting of stockholders to be held virtually on April 17, 2024. The primary agenda is to seek approval for a reverse stock split of issued common stock at a ratio between 1-for-2 and 1-for-50, at the board's discretion, without further stockholder approval. This move aims to avoid delisting from Nasdaq, attract brokerage firms and investors, and facilitate future financings. The company also seeks approval to adjourn the meeting if necessary to solicit more votes for the reverse stock split. The record date for determining stockholders eligible to vote is March 5, 2024. The company encourages stockholders to vote by proxy prior to the meeting, with detailed voting instructions provided. The reverse stock split is intended as a recapitalization for tax purposes, with no gain or loss recognized by the company or stockholders. The board recommends voting 'FOR' both the reverse stock split and the potential adjournment.
ZyVersa Therapeutics, Inc.已宣佈將於2024年4月17日虛擬舉行股東特別會議。主要議程是尋求批准以1比2和1比50的比例對已發行普通股進行反向分割，由董事會自行決定，無需進一步獲得股東的批准。此舉旨在避免從納斯達克退市，吸引經紀公司和投資者，並促進未來的融資。如有必要，該公司還尋求批准休會，以爭取更多反向股票拆分的選票。確定有資格投票的股東的記錄日期是2024年3月5日。該公司鼓勵股東在會議之前通過代理人進行投票，並提供詳細的投票說明。反向股票拆分旨在出於稅收目的進行資本重組，公司或股東不確認損益。董事會建議對反向股票拆分和可能的休會投贊成票。
ZyVersa Therapeutics, Inc.已宣佈將於2024年4月17日虛擬舉行股東特別會議。主要議程是尋求批准以1比2和1比50的比例對已發行普通股進行反向分割，由董事會自行決定，無需進一步獲得股東的批准。此舉旨在避免從納斯達克退市，吸引經紀公司和投資者，並促進未來的融資。如有必要，該公司還尋求批准休會，以爭取更多反向股票拆分的選票。確定有資格投票的股東的記錄日期是2024年3月5日。該公司鼓勵股東在會議之前通過代理人進行投票，並提供詳細的投票說明。反向股票拆分旨在出於稅收目的進行資本重組，公司或股東不確認損益。董事會建議對反向股票拆分和可能的休會投贊成票。
有用
沒用